Hepatitis C therapy with HCV NS5B polymerase inhibitors

UNITAID can address HCV/HIV co-infection

(2013) Tido von Schoen-Angerer et al.   LANCET

Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C

(2013) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

(2013) Edward J. Gane et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus

(2012) Angela M. Lam et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The changing face of hepatitis C in the new era of direct-acting antivirals

(2012) Vincent Soriano et al.   ANTIVIRAL RESEARCH

Non-nucleoside Analogue Polymerase Inhibitors in Development

(2012) Paul J. Pockros   Clinics in Liver Disease

Nucleoside/Nucleotide Analogue Polymerase Inhibitors in Development

(2012) Paul J. Pockros   Clinics in Liver Disease

Interferon-Free Hepatitis C Therapy

(2012) Paul J. Pockros   DRUGS

Treatment failure with new hepatitis C drugs

(2012) Vincent Soriano et al.   EXPERT OPINION ON PHARMACOTHERAPY

Current prospects for interferon-free treatment of hepatitis C in 2012

(2012) Catherine AM Stedman   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study

(2012) M.-H. Lee et al.   JOURNAL OF INFECTIOUS DISEASES

Challenges and Priorities in the Management of HIV/HBV and HIV/HCV Coinfection in Resource-Limited Settings

(2012) Philippa Easterbrook et al.   SEMINARS IN LIVER DISEASE

Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV–HCV-coinfected patients

(2011) Ana Treviño et al.   ANTIVIRAL THERAPY

Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients

(2011) Inmaculada Jiménez-Nácher et al.   Expert Opinion on Drug Metabolism & Toxicology

Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection

(2011) Stefan Zeuzem et al.   GASTROENTEROLOGY

Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations

(2011) Natasha K. Martin et al.   HEPATOLOGY

Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin

(2011) Kris V. Kowdley et al.   HEPATOLOGY

Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients

(2011) Z. Plaza et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

61 ONCE DAILY PSI-7977 PLUS PEGIFN/RBV IN A PHASE 2B TRIAL: RAPID VIROLOGIC SUPPRESSION IN TREATMENT-NAIVE PATIENTS WITH HCV GT2/GT3

(2011) J. Lalezari et al.   JOURNAL OF HEPATOLOGY

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review

(2011) Christian Thoma et al.   JOURNAL OF HEPATOLOGY

Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility

(2010) Natasha K. Martin et al.   JOURNAL OF HEPATOLOGY

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

(2010) Edward J Gane et al.   LANCET

1052 ANTIVIRAL ACTIVITY OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS IN TREATMENT NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 1

(2009) I. Jacobson et al.   JOURNAL OF HEPATOLOGY